Home Data Calendar Blog

BBIO

Tables

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Common Stock Value 0.200.190.190.180.180.170.170.160.160.150.150.150.150.150.150.120.120.120.12
Weighted Average Number Of Diluted Shares Outstanding 188.51187.59178.71NA163.31160.54152.65NA147.94146.68145.88NA146.66146.75NANANANANA
Weighted Average Number Of Shares Outstanding Basic 188.51187.59178.71NA163.31160.54152.65NA147.94146.68145.88NA146.66146.75NANANANANA
Earnings Per Share Basic -0.86-0.39-0.20-0.96-1.08-0.98-0.92-0.92-0.93-0.07-1.35-1.02-1.06-0.66NANANANANA
Earnings Per Share Diluted -0.86-0.39-0.20-0.96-1.08-0.98-0.92-0.92-0.93-0.07-1.35-1.02-1.06-0.66NANANANANA

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Revenue From Contract With Customer Excluding Assessed Tax 2.732.17211.121.754.091.641.831.870.3473.751.6912.892.3454.020.460.128.1313.8226.74
Revenues 2.732.17211.121.754.091.641.831.870.3473.751.6912.892.3454.020.460.128.1313.8226.74
Cost Of Revenue 0.600.600.600.600.600.600.650.650.740.70NA1.551.450.11NANANANANA
Cost Of Goods And Services Sold 0.600.600.600.600.600.600.650.650.740.70NA1.171.450.11NANANANANA
Costs And Expenses 194.48177.71210.78179.16161.78147.74127.99131.10129.45153.92175.37178.50151.84148.04167.97127.61128.07NANA
Research And Development Expense 120.44114.69140.97130.23125.14107.4992.8690.9092.51108.40107.65122.20104.31101.96122.5690.1792.0557.4855.28
Selling General And Administrative Expense 68.8259.5265.8147.5835.7836.1231.1131.8631.1936.4343.7154.7546.0845.9745.4137.4436.02NANA
Operating Income Loss -191.75-175.540.34-177.42-157.69-146.10-126.16-129.23-129.12-80.18-173.68-165.61-149.50-94.02-167.50-127.49-119.94-78.64-54.53
Interest Expense Debt 8.598.588.578.578.568.558.558.548.548.538.538.528.518.517.10NA8.21NANA
Interest Paid Net 29.1913.7335.3110.2822.096.6822.066.8722.146.6318.811.5317.431.908.912.049.161.761.75
Gains Losses On Extinguishment Of Debt 0.000.00-26.59NANANANANANANANANANANANANANANANA
Allocated Share Based Compensation Expense 27.1321.4528.8537.1327.2327.1823.4822.5818.6628.3024.2822.5116.1332.0334.9012.1517.7010.015.78
Profit Loss -164.25-75.54-36.16-170.33-179.49-160.70-142.73-140.57-140.19-2.56-201.33-152.28-161.02-102.07-171.08-135.03-130.17-84.15-60.66
Comprehensive Income Net Of Tax -162.03-73.46-35.24-168.15-177.03-157.82-139.84-137.57-137.26-9.90-196.65-147.33-155.95-96.25-163.33-120.25-116.26-56.05-60.51
Net Income Loss Available To Common Stockholders Basic -162.04-73.46-35.22-168.15-177.00-157.90-140.16-137.59-137.34-9.86-196.40-147.18-155.94-96.35-163.08-119.98-115.86-73.46-59.98

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Assets 664.98794.38849.33546.38655.01503.66625.68623.04728.74862.23813.151012.79781.521081.491093.31703.59787.69631.68640.53
Liabilities 1883.371876.471886.191888.911848.741853.301839.291867.961859.111877.251853.841878.371517.401537.111481.40595.70569.31155.70116.26
Liabilities And Stockholders Equity 664.98794.38849.33546.38655.01503.66625.68623.04728.74862.23813.151012.79781.521081.491093.31703.59787.69631.68640.53
Stockholders Equity -1229.92-1092.92-1049.53-1354.26-1207.54-1362.02-1225.66-1254.62-1138.42-1025.53-1041.00-870.41-743.40-464.29-395.2957.91163.76408.45459.76

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Assets Current 444.58616.24783.42477.59587.67432.88552.70548.85642.22771.28716.23888.86639.71909.87945.11642.82745.38568.62558.15
Cash And Cash Equivalents At Carrying Value 266.32407.96475.22375.94505.21302.44407.37376.69483.24470.10371.55393.77180.35378.42471.18356.08366.97363.77413.97
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 407.88549.51477.50394.73524.14324.64435.11416.88485.79472.65374.19396.37183.08381.13473.77358.68NANANA
Prepaid Expense And Other Assets Current 38.3728.4028.1124.3022.5820.5525.1421.9225.6632.7534.0232.4531.9326.6725.5335.7326.7022.6322.10

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Amortization Of Intangible Assets 0.600.600.600.600.600.600.600.600.600.600.901.300.70NANANANANANA
Property Plant And Equipment Net 8.709.8411.4111.8212.4113.0513.5714.5715.6016.8717.1830.0727.7426.2722.8220.3216.185.622.98
Investments In Affiliates Subsidiaries Associates And Joint Ventures 160.44117.01NANANANANANANANANANANANANANANANA0.91
Intangible Assets Net Excluding Goodwill 24.5225.1225.7226.3226.9227.5228.1128.7129.3129.9130.4844.9346.20NANANANANANA
Finite Lived Intangible Assets Net 24.5225.1225.7226.3226.9227.5228.1128.7129.3129.9130.4844.9346.20NANANANANANA
Other Assets Noncurrent 20.2918.9020.7222.6218.6820.4020.7720.2229.8731.3235.3333.0333.0549.8030.1823.9316.4826.292.60

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Liabilities Current 139.22134.36141.48143.84106.06110.1296.60121.43119.19141.16103.46135.0795.82131.9194.7395.6575.7160.3839.86
Accounts Payable Current 13.3618.134.7310.654.473.874.0811.5610.168.7910.1111.8812.0422.3310.348.959.848.8510.27
Other Accrued Liabilities Current 12.969.0510.884.66NA6.2322.2225.1923.8431.9824.7830.2814.6121.1818.2513.35NA3.023.22

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Long Term Debt Noncurrent 436.22435.45434.72446.44441.72440.50435.76430.99NANA434.11430.75103.14102.6190.7692.4293.3991.7975.02
Minority Interest 10.8811.0512.1411.2412.4012.0512.2611.2810.4312.02-0.033.414.566.805.9348.3552.0665.2861.94
Other Liabilities Noncurrent 0.380.480.599.3611.7913.3317.5026.6428.2328.6326.8322.0727.5813.2711.619.5213.473.531.39
Operating Lease Liability Noncurrent 5.837.068.308.989.8110.9211.9012.2713.0014.2815.4917.4318.6818.0213.8614.688.24NANA

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Stockholders Equity -1229.92-1092.92-1049.53-1354.26-1207.54-1362.02-1225.66-1254.62-1138.42-1025.53-1041.00-870.41-743.40-464.29-395.2957.91163.76408.45459.76
Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1219.04-1081.87-1037.38-1343.01-1195.14-1349.97-1213.41-1243.34-1127.98-1013.51-1041.02-867.00-738.84-457.49-389.37106.26215.81473.73521.70
Common Stock Value 0.200.190.190.180.180.170.170.160.160.150.150.150.150.150.150.120.120.120.12
Additional Paid In Capital Common Stock 1876.091851.061820.991481.031459.601128.101106.63938.70917.33892.96867.60841.53821.22799.68767.121021.341006.94848.11826.06
Retained Earnings Accumulated Deficit -2831.21-2669.17-2595.72-2560.50-2392.35-2215.35-2057.45-1918.15-1780.56-1643.22-1633.36-1436.97-1289.79-1133.85-1037.51-888.75-768.77-440.03-366.57
Accumulated Other Comprehensive Income Loss Net Of Tax 0.01-0.000.000.030.030.06-0.01-0.33-0.35-0.43-0.38-0.130.020.04-0.060.190.460.25NA
Treasury Stock Value 275.00275.00275.00275.00275.00275.00275.00275.00275.00275.00275.00275.00275.00130.31125.0075.00NANANA
Minority Interest 10.8811.0512.1411.2412.4012.0512.2611.2810.4312.02-0.033.414.566.805.9348.3552.0665.2861.94
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 26.6531.5027.12NA24.2324.6124.33NA23.2323.9025.42NA16.9032.5119.84NA11.75NANA

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Net Cash Provided By Used In Operating Activities -180.5774.70-219.54-124.82-145.23-113.35-144.32-93.24-135.16-30.45-160.63-133.90-121.56-91.71-150.76-96.26-131.68-76.20-50.00
Net Cash Provided By Used In Investing Activities 38.233.0422.75-0.0737.684.1212.3017.96146.86149.70138.6221.8058.970.46-282.0583.02-45.05-16.90-197.34
Net Cash Provided By Used In Financing Activities 0.71-5.73279.55-4.52307.04-1.23150.256.381.45-20.80-0.16325.38-135.46-1.39547.914.532.7842.90367.51

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Net Cash Provided By Used In Operating Activities -180.5774.70-219.54-124.82-145.23-113.35-144.32-93.24-135.16-30.45-160.63-133.90-121.56-91.71-150.76-96.26-131.68-76.20-50.00
Profit Loss -164.25-75.54-36.16-170.33-179.49-160.70-142.73-140.57-140.19-2.56-201.33-152.28-161.02-102.07-171.08-135.03-130.17-84.15-60.66
Depreciation Depletion And Amortization 1.541.571.601.581.641.641.631.661.651.581.881.530.273.490.570.43-1.01NANA
Increase Decrease In Accounts Payable -3.6014.79-5.936.180.69-0.30-3.801.381.36-1.28-1.811.47-11.6611.231.79-1.28-3.44-1.42-3.38
Share Based Compensation 27.1621.4517.0637.0222.6027.1821.9121.7917.3628.2924.1219.7716.0430.1133.5812.1517.7010.015.78

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Net Cash Provided By Used In Investing Activities 38.233.0422.75-0.0737.684.1212.3017.96146.86149.70138.6221.8058.970.46-282.0583.02-45.05-16.90-197.34
Payments To Acquire Property Plant And Equipment 0.140.050.690.430.430.430.010.800.762.400.862.546.462.291.962.150.551.750.38

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Net Cash Provided By Used In Financing Activities 0.71-5.73279.55-4.52307.04-1.23150.256.381.45-20.80-0.16325.38-135.46-1.39547.914.532.7842.90367.51

    2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2019-12-31 2019-09-30
Revenues 2.732.17211.121.754.091.641.831.870.3473.751.6912.892.3454.020.460.128.1313.8226.74
Eidos Therapeutics Inc, License, Bayer Exclusive License Agreement 0.300.40NANANANANANANANANANANANANANANANANA
Eidos Therapeutics Inc, Bayer Exclusive License Agreement 0.300.40NANANANANANANANANANANANANANANANANA
Bristol Myers Squibb Company, Navire Pharma Inc, Sales, License And Collaboration Agreement 0.000.009.900.901.301.501.701.40NANANANANANANANANANANA
Q E D Therapeutics Inc, License, Kyowa Kirin Exclusive License 2.101.30NANANANANANANANANANANANANANANANANA
Q E D Therapeutics Inc, Kyowa Kirin Exclusive License 1.401.301.60NANANANANANANANANANANANANANANANA
Q E D Therapeutics Inc, Letter Of Agreement 0.70NANANANANANANANANANANANANANANANANANA
Revenue From Contract With Customer Excluding Assessed Tax 2.732.17211.121.754.091.641.831.870.3473.751.6912.892.3454.020.460.128.1313.8226.74
Eidos Therapeutics Inc, License, Bayer Exclusive License Agreement 0.300.40NANANANANANANANANANANANANANANANANA
Eidos Therapeutics Inc, Bayer Exclusive License Agreement 0.300.40NANANANANANANANANANANANANANANANANA
Bristol Myers Squibb Company, Navire Pharma Inc, Sales, License And Collaboration Agreement 0.000.009.900.901.301.501.701.40NANANANANANANANANANANA
Q E D Therapeutics Inc, License, Kyowa Kirin Exclusive License 2.101.30NANANANANANANANANANANANANANANANANA
Q E D Therapeutics Inc, Kyowa Kirin Exclusive License 1.401.301.60NANANANANANANANANANANANANANANANA
Q E D Therapeutics Inc, Letter Of Agreement 0.70NANANANANANANANANANANANANANANANANANA

Plots across concepts


IncomeStatement
Operating Income Loss
Balance Sheet
Stockholders Equity
Assets
Operating Lease Right Of Use Asset
Current Assets
Prepaid Expense And Other Assets Current
NonCurrent Assets
Operating Lease Right Of Use Asset
Liabilities
Operating Lease Liability
Current Liabilities
Operating Lease Liability Current
Noncurrent Liabilities
Other Liabilities Noncurrent
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInInvestingActivities
Payments To Acquire Property Plant And Equipment
NetCashProvidedByUsedInFinancingActivities
Proceeds From Issuance Of Long Term Debt
Shares
Weighted Average Number Of Diluted Shares Outstanding
OperatingLeaseLiability
Operating Lease Liability Current
NonoperatingIncomeExpense
Other Nonoperating Income Expense
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Payments Due Year Four
FiniteLivedIntangibleAssets
Finite Lived Intangible Assets Accumulated Amortization

Line plots across dimensions of each concept